This indicates that not only is SirT1 enhancement an approach for development of new AD drugs, it could be a predictive biomarker of AD in early stages and useful in clinical testing of this class of ApoE4 targeted therapeutic. This evidence concerns the gene APOE and Alzheimer disease.